{
    "nctId": "NCT01407562",
    "briefTitle": "Study of Pazopanib, Paclitaxel, and Carboplatin in Patients With Advanced Solid Tumors",
    "officialTitle": "Phase I Study of Pazopanib in Combination With Weekly Paclitaxel and Carboplatin to Assess the Safety and Tolerability in Patients With Advanced Solid Tumors",
    "overallStatus": "TERMINATED",
    "conditions": "Unspecified Adult Solid Tumor - Protocol Specific, Breast Cancer - Female",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 34,
    "primaryOutcomeMeasure": "Establish the maximum tolerated dose (MTD) of pazopanib with weekly paclitaxel and carboplatin on a 28- day cycle",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Confirmed diagnosis of a solid malignancy with advanced disease that has relapsed, that is refractory to standard therapies, or for which there is not standard therapy, or for which the patient opts not to receive standard therapy.\n* At the recommended phase II dose level, triple-negative breast cancer defined as ER-negative, PR-negative, and HER2-negative, will be enrolled and another 10 patients with a solid malignancy who would benefit from a paclitaxel and carboplatin-based regimen, will also be enrolled.\n* Male or female \u2265 18 years of age\n* Able to swallow and retain oral medications\n\nExclusion Criteria:\n\n* Major surgery within last 28 days or cytotoxic chemotherapy, biologic therapy, investigational agents, or radiotherapy within last 21 days. Patients who have completed therapy with mitomycin C or nitrosurea will have to wait 42 days.\n* More than 3 prior lines of cytotoxic chemotherapy for metastatic disease",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}